Fake medicines targeted in joint EU customs operation

Published: 4-Aug-2014

More than 70,000 counterfeit drugs are seized


Counterfeit medicines smuggled into Europe through the post and by couriers were among more than 70,000 fake products intercepted during a joint customs operation code-named ERMIS.

Coordinated by the Greek customs service and the European Union (EU) anti-fraud office OLAF, the operation involved customs officers from other EU member states, including Macedonia, Montenegro, Serbia and Turkey, said the European Commission.

See more

You may also like

Distribution

ChargePoint invest in a single-use manufacturing facility to expand product line

Read more
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices

Trending Articles

  1. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  2. Fasenra for EGPA: addressing unmet needs Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  4. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  5. Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Distribution

ChargePoint invest in a single-use manufacturing facility to expand product line

The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Research & Development

Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool

The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Manufacturing

Optimising RNA production for faster and cheaper pharmaceutical manufacturing

RNA production can be a lengthy and complex process, but the Ntensify platform could change this by diminishing development times, decreasing production costs and allowing the avoidance of scaling issues
Research & Development

New automated tissue dissociation systems

Introducing the new Singulator series (100 and 200)
Packaging

SÜDPACK’s greenhouse gas reduction targets validated by the SBTi

The company aims to reduce scope 1 & 2 greenhouse gas emissions by 76%, as well as a 25% reduction in scope 3 emissions
Distribution

Tower Cold Chain’ industry-first shipping container design

The pyramidal solution allows pharmaceuticals to be shipped at a consistent temperature between -60°C to above +20°C for up to 96 hours
Manufacturing

Memel Biotech and Therabest collaborate to develop exosome-based cell therapies

The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Subscribe now